Stoke Therapeutics Inc
STOK
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.8B
Close$
$-2.95
109.3% downside
Current Fair Value
109.3% downsideOvervalued by 109.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.80 Billion |
|---|---|
| Enterprise Value | $1.65 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.12 |
| Beta | 1.18 |
| Outstanding Shares | 63,063,507 |
Return
| Return on Equity | -42.99% |
|---|---|
| Return on Assets | -38.30% |
| Return on Invested Capital | -46.03% |
Valuation & Multiples
| P/E Ratio | -10.2 |
|---|---|
| PEG | 7.07 |
| Price to Sales | - |
| Price to Book Ratio | 5.28 |
| Enterprise Value to Revenue | 51.49 |
| Enterprise Value to EBIT | -8.92 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 3, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
$4.89 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.82
Average shareholder expectationRevenue Estimate
$4.89 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 245.40% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.81%▼ 117.26% |
|---|---|
| Total Invested | $57.91M▼ 97.50% |
| Investors Holding | 26▼ 178.00% |
ESG Score
No data
About Stoke Therapeutics Inc
CEO: Edward Kaye